Caplin One Labs, a wholly owned subsidiary of Caplin Point Laboratories, has completed its oncology facility at Kakkalur, near Chennai, and announced immediate commencement of operations. The total investment commitment for this facility is Rs 150 crore, funded entirely from internal accruals.

The unit will focus on manufacturing a range of oral solid dosage oncology products, with the injectable division to commence operations in the next few months. The company plans to expand the portfolio to over 50 oncology products.

The facility will manufacture tablets (both coated & uncoated), capsules, and injections, catering to the growing demand for high-quality pharmaceuticals in the oncology segment. Initially, these oncology products will be targeted at Latin American countries, leveraging Caplin Group's established presence in these markets.

With the objective of advancing healthcare solutions and improving patient outcomes, Caplin One Labs in the medium term aims to launch these oncology products in regulated markets such as the US, EU, Mexico, and others.

Caplin Point Laboratories has modern manufacturing facilities which cater to a complete range of finished dosage forms. Overall, Caplin Group is committed to delivering superior pharmaceutical products and increase its market footprint.